Resight Therapeutics

Resight Therapeutics was founded in September 2024, focusing on the research and development of cell-based therapeutic drugs and addressing significant unmet clinical needs in ocular diseases. The company's team has over 10 years of experience in basic and clinical research on cell therapies for ophthalmic diseases, as well as experience in the stem cell industry, with research achievements published multiple times in top international journals. Resight Therapeutics is leveraging its self-developed iPSC differentiation technology platform and AI+ compound reprogramming technology platform to focus on developing breakthrough cell therapies urgently needed for corneal and retinal diseases. Resight Therapeutics has established collaborations with several top ophthalmology research institutions and hospitals to accelerate the clinical translation of innovative therapies for ocular diseases, providing patients with higher quality and safer treatment options.